Role of L-arginine in the treatment of reduced amniotic fluid
Not Applicable
- Conditions
- Health Condition 1: O410- Oligohydramnios
- Registration Number
- CTRI/2024/02/062282
- Lead Sponsor
- Dr Deepita vais
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. From 28-37 weeks POG.
2. Singleton pregnancy.
3. AFI less than 8.
4. Membrane should be intact.
Exclusion Criteria
1. Smoking.
2. Foetal malformation.
3. Severe pre- eclampsia.
4 . Abnormal foetal Doppler.
5. Premature rupture of membrane.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the role of L-arginine in the treatment of oligohydramnios.Timepoint: Every week till delivery
- Secondary Outcome Measures
Name Time Method To determine the efficacy of L-arginine as a treatment modality in oligohydramniosTimepoint: Every week till delivery